Two phase 2 studies are evaluating the activity of APX005M administered at two different schedules in patients with unresectable melanoma (NCT04337931) and an ongoing trial is evaluating neoadjuvant therapy with or without CD40 agonistic APX005M for locally advanced rectal carcinoma (NCT04130854). This evidence concerns the gene CD40 and melanoma.